Literature DB >> 1993788

Concealed entrainment as a guide for catheter ablation of ventricular tachycardia in patients with prior myocardial infarction.

F Morady1, A Kadish, S Rosenheck, H Calkins, W H Kou, M De Buitleir, J Sousa.   

Abstract

Fifteen consecutive patients with drug-refractory, recurrent, sustained, monomorphic ventricular tachycardia and a history of remote myocardial infarction underwent catheter ablation of ventricular tachycardia. Shocks of 100 to 300 J were delivered to sites at which pacing during ventricular tachycardia resulted in concealed entrainment, in which the ventricular tachycardia accelerated to the pacing rate, there was a long stimulus to QRS interval and there was no change in the configuration of the QRS complex during pacing at several rates compared with the configuration during ventricular tachycardia, thus identifying a zone of slow conduction in the reentrant circuit. Concealed entrainment was demonstrated in nine (60%) of 15 patients, and the stimulus to QRS intervals were 90 to 400 ms. At sites of concealed entrainment, the endocardial activation time relative to the QRS complex during ventricular tachycardia ranged from -125 to +50 ms, the timing of the local electrogram relative to the QRS complex was the same during entrainment as during ventricular tachycardia and the pace map during sinus rhythm was discordant with that of the ventricular tachycardia in seven patients. In the six patients in whom a site of concealed entrainment could not be identified, the target site for ablation was selected on the basis of identification of an isolated mid-diastolic potential, activation mapping and pace mapping. The mean (+/- SD) cumulative number of joules delivered to the target site was 306 +/- 140. A successful long-term clinical outcome was achieved in 9 of the 15 patients (mean follow-up 20 +/- 7 months). The clinical success rate was the same whether the target site was selected on the basis of concealed entrainment (five of nine, 56%) or on the basis of the other mapping techniques (four of six, 67%). In conclusion, the responses to pacing suggest that sites at which there is concealed entrainment may be located within a zone of slow conduction in the ventricular tachycardia reentry circuit, although not necessarily in an area critical for the maintenance of reentry. The long-term clinical efficacy of catheter ablation targeted to sites of concealed entrainment is about 60%, similar to the results achieved when conventional mapping techniques are used.

Entities:  

Mesh:

Year:  1991        PMID: 1993788     DOI: 10.1016/s0735-1097(10)80184-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  15 in total

Review 1.  [Cardiology update. I: Electrophysiology].

Authors:  P Weismüller; H J Trappe
Journal:  Med Klin (Munich)       Date:  1999-01-15

Review 2.  Telomerase-independent mechanisms of telomere elongation.

Authors:  H Biessmann; J M Mason
Journal:  Cell Mol Life Sci       Date:  2003-11       Impact factor: 9.261

3.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Saenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  J Interv Card Electrophysiol       Date:  2020-10       Impact factor: 1.900

4.  Substrate-modification using electroanatomical mapping in sinus rhythm to treat ventricular tachycardia in patients with ischemic cardiomyopathy.

Authors:  T Deneke; P H Grewe; T Lawo; B Calcum; A Mügge; B Lemke
Journal:  Z Kardiol       Date:  2005-07

5.  Case report: Symptoms of advanced heart failure--a case for radiofrequency catheter ablation?

Authors:  Alan Bulava; Petr Heinc; Martin Hutyra; Milan Kaminek; Malvina Krivankova; Marek Richter; Jan Lukl
Journal:  J Interv Card Electrophysiol       Date:  2006-10-24       Impact factor: 1.900

Review 6.  Radiofrequency catheter ablation: a new frontier in interventional cardiology.

Authors:  Y Bashir; D E Ward
Journal:  Br Heart J       Date:  1994-02

7.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Sáenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  Europace       Date:  2019-08-01       Impact factor: 5.214

Review 8.  Ablation of ventricular tachycardia in the setting of coronary artery disease.

Authors:  A W Richardson; M E Josephson
Journal:  Curr Cardiol Rep       Date:  1999-07       Impact factor: 2.931

Review 9.  Catheter ablation of ventricular tachycardia. From indication to three-dimensional mapping technology.

Authors:  Lars Eckardt; Günter Breithardt
Journal:  Herz       Date:  2009-05       Impact factor: 1.443

Review 10.  Non-contact mapping in the treatment of ventricular tachycardia after myocardial infarction.

Authors:  Kim Rajappan; Richard J Schilling
Journal:  J Interv Card Electrophysiol       Date:  2007-06-28       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.